Leadership

Joseph E. Payne, President & CEO, Director of the BoardJoseph E. Payne, President & CEO, Director of the BoardJoseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.

Padmanabh Chivukula, CSO & COOPadmanabh Chivukula, CSO & COOPad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.

Andrew Sassine, Chief Financial OfficerAndrew Sassine, Chief Financial OfficerAndy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. ICAD Inc. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2005 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.

Dr. Steve Hughes, Chief Medical OfficerDr. Steve Hughes, Chief Medical OfficerDr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases. Prior to that he was Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of multiple drugs across several therapeutic areas. He has also held positions at Biogen Idec, CSL Behring and Sanofi. Dr. Hughes is Board Certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.

Lance Kurata, Chief Legal OfficerLance Kurata, Chief Legal OfficerLance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to Arcturus, from 2006 to 2020, Mr. Kurata was a partner at Mintz Levin and Chair of the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson, where he was a member of the corporate group and nationwide head of the technology transactions practice. From 1996 until 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, specializing in strategic collaborations, public and private financings, mergers and acquisitions and corporate governance. Mr. Kurata is licensed to practice law in the State of California. He received his Juris Doctor (JD) degree from Stanford Law School and was an editor of Stanford Law Review.

Dushyant Varshney, EVP & Chief Technology OfficerDushyant Varshney, EVP & Chief Technology OfficerDushyant B. Varshney, Ph.D., is the Executive Vice President & Chief Technology Officer. He is responsible for Global CMC, Technical Operations & Quality, including technology innovation, product development, manufacturing, technology transfer and commercialization of Drug Substance and Finished Drug Products. Dr. Varshney has over 25 years of experience at global bio-pharma organizations, leading the entire product life-cycle of diverse biotech modalities including mRNA therapeutics, gene & cell-based therapy, biologics and vaccines. He has made significant contributions towards 30+ launches, 75+ INDs, BLA, PAS submissions, and ensured supply of more than 7B+ doses, $20B+ revenues at companies including Gilead, Pfizer, Novartis and Sanofi. Before joining Arcturus, Dr. Varshney was the Global Head of Manufacturing, Science & Technology at Gilead-Kite, where he built a strong organization & rapid commercialization strategy for successful technology transfers, launch & patient access of Yescarta®, Tecartus®, viral vectors and clinical products. Prior to that, he served as the Vice President, Global Head of Technical Services, Operations & Supply at Jubilant, and as the Head of Manufacturing, Science & Technology at Pfizer, led America, Europe & Asia Pacific teams. At Novartis, contributed to commercial technology transfer, qualification, manufacturing of Flucelvax® (first US cell-based influenza vaccine) Trivalent & Quadrivalent, Pre-Pandemic Vaccine stockpiles (bird & swine-flu, H5N1, H3N2, H7N9), and pandemic response strategies. Dushyant received his Ph.D. in Chemistry from University of Iowa, M. Pharm from Institute of Chemical Technology, Mumbai, and B. Pharm from University of Pune in India. He is a Stephen Covey Leadership Coach, Master Black-Belt in Operational Excellence, made 120+ conference presentations, published 40+ articles, chapters and edited the book “Lyophilized Biologics & Vaccines” published by Springer.

Nirdosh Jagota, Executive Vice President & Chief Regulatory OfficerNirdosh Jagota, Executive Vice President & Chief Regulatory OfficerNirdosh Jogota, Ph.D., is responsible for regulatory affairs at Arcturus and joins the company with more than 30 years of experience in leading roles in drug development, quality, and regulatory sciences for vaccines, biologics and small molecules. Most recently, he was Senior Vice President in Global Regulatory Affairs and Clinical Safety at Merck and Co. At Merck, where he oversaw engagement and strategy with regulatory agencies across the world, including those in the United States, Europe, Latin America, Canada, Japan, and China. Prior to Merck, Nirdosh was Vice President of Regulatory at Genentech and Pfizer. Previously he worked at Sanofi and Bristol-Myers Squibb. Nirdosh has led and contributed to the development, submission, and approval of more than 30 vaccines, small molecules, and biologics in his career. Dr. Jagota holds a Ph.D. in clinical pharmacokinetics and pharmaceutical sciences from University of Georgia, MS in biotechnology from University of Toledo, Ohio, and a BS/MS in pharmacy from Indian Institute of Technology (IIT) Varanasi. Dr. Jagota has served on several committees of the Pharmaceutical Research and Manufacturers of America (PhRMA) including the Regulatory Sciences steering committee. He is also the past chair of Regulatory Science section of the American Association of Pharmaceutical Scientists (AAPS), the Drug Information Association (DIA), and International Society for Pharmaceutical Engineering (ISPE). He currently serves on the “One-Voice-of-Quality” committee for the Parenteral Drug Association (PDA). Dr. Jagota is also member of the Advisory committee for College of Pharmacy Graduate program at University of Georgia. Dr. Jagota is an active sponsor of Sharing Science Solutions (CASSS) and a founding member of the CASSS Japan and China forum, which is a leading organization for converging Quality requirements in Japan and China with the International Council for Harmonization (ICH) for biologics and Vaccines Development.

News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
March 1, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
READ MORE
March 30, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
May 3, 2021
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
READ MORE
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
READ MORE
June 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
July 26, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
READ MORE
July 28, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
READ MORE
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
READ MORE
August 2, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
August 3, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
READ MORE
August 9, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
READ MORE
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
READ MORE
September 8, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
READ MORE
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
READ MORE
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
READ MORE
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
READ MORE